Skip to main content
. 2021 Aug 21;40(1):68–80. doi: 10.1007/s10637-021-01156-9

Table 2.

In vitro inhibition of human drug metabolizing enzymes and transport proteins by entrectinib and M5

IC50 (µM)
Entrectinib M5

Drug Metabolizing

Enzymes

CYP1A2  > 10  > 10
CYP2B6  > 10  > 10
CYP2C8  > 10 4.9
CYP2C9  > 10  > 10
CYP2C19  > 10  > 10
CYP2D6  > 10  > 10
CYP3A4/5 2.0  > 10
Transport Proteins MDR1 (P-gp) 1.3 10

CYP cytochrome P450, MDR multidrug resistance, P-gp P-glycoprotein

Entrectinib was a very weak time-dependent inhibitor (TDI) of CYP3A4 but KI and kinact could not be measured in vitro as the TDI signal was too low